ZHX2 mediates proteasome inhibitor resistance via regulating nuclear translocation of NF‐κB in multiple myeloma
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
ZHX2 mediates proteasome inhibitor resistance via regulating nuclear translocation of NF‐κB in multiple myeloma
Authors
Keywords
-
Journal
Cancer Medicine
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2020-08-12
DOI
10.1002/cam4.3347
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins
- (2019) Rumani Singh et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- ZHX2 inhibits proliferation and promotes apoptosis of human lung cancer cells through targeting p38MAPK pathway
- (2019) Xudong Tian et al. Cancer Biomarkers
- An investigation of the mechanisms underlying the proteasome inhibitor bortezomib resistance in PC3 prostate cancer cell line
- (2019) Azmi Yerlikaya et al. CYTOTECHNOLOGY
- Repurposing old drugs as new inhibitors of the ubiquitin-proteasome pathway for cancer treatment
- (2019) Huanjie Yang et al. SEMINARS IN CANCER BIOLOGY
- Transcription FactorZhx2Deficiency Reduces Atherosclerosis and Promotes Macrophage Apoptosis in Mice
- (2018) Ayca Erbilgin et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- NF-κB-IKKβ pathway as a target for drug development: realities, challenges and perspectives
- (2018) Rosana H.C.N. Freitas et al. CURRENT DRUG TARGETS
- HBV suppresses ZHX2 expression to promote proliferation of HCC through miR-155 activation
- (2018) Xiaojia Song et al. INTERNATIONAL JOURNAL OF CANCER
- NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018
- (2018) Shaji K. Kumar et al. Journal of the National Comprehensive Cancer Network
- VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma
- (2018) Jing Zhang et al. SCIENCE
- Targeting Bcl-2 for the treatment of multiple myeloma
- (2018) Cyrille Touzeau et al. LEUKEMIA
- The impact of NF-κB signaling on pathogenesis and current treatment strategies in multiple myeloma
- (2018) Dávid Vrábel et al. BLOOD REVIEWS
- Proteasome inhibitors in cancer therapy
- (2017) Elisabet E. Manasanch et al. Nature Reviews Clinical Oncology
- VHL Deficiency Drives Enhancer Activation of Oncogenes in Clear Cell Renal Cell Carcinoma
- (2017) Xiaosai Yao et al. Cancer Discovery
- Multiple myeloma
- (2017) Shaji K. Kumar et al. Nature Reviews Disease Primers
- Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling
- (2016) Xing-Ding Zhang et al. CANCER CELL
- Revisiting IL-6 antagonism in multiple myeloma
- (2016) Thomas Matthes et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models
- (2016) E. A. Punnoose et al. MOLECULAR CANCER THERAPEUTICS
- Multiple myeloma
- (2015) Christoph Röllig et al. LANCET
- The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma
- (2014) A. Spencer et al. BLOOD
- Reduced nucleic ZHX2 involves in oncogenic activation of glypican 3 in human hepatocellular carcinoma
- (2014) Fang Luan et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- Regulation of NF-κB by ubiquitination and degradation of the IκBs
- (2012) Naama Kanarek et al. IMMUNOLOGICAL REVIEWS
- Different mutants of PSMB5 confer varying bortezomib resistance in T lymphoblastic lymphoma/leukemia cells derived from the Jurkat cell line
- (2009) Shuqing Lü et al. EXPERIMENTAL HEMATOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started